Researchers standardise test for predicting transplant rejection

May 29, 2019

Researchers from The Westmead Institute for Medical Research have developed a standardised method of measuring the immune response in islet transplant recipients, helping predict patient outcomes.

Islet transplantation is a frontier therapy for type 1 diabetes with notable success in hypoglycaemic patients, where pancreatic beta cells from a donor are transplanted into a recipient, enabling the body to produce insulin, and regulate blood sugar.

Transplant recipients are given immunosuppressant medication to prevent the immune system from attacking and destroying the transplant. However, rejection may still occur in certain instances.

Lead researcher Dr Min Hu and her team aimed to standardise a method using flow cytometry - technology that detects and measures the characteristics of a group of cells - to analyse the immune cells present in blood samples.

The research built on existing findings, which established that certain profiling panels (sets of characteristics that are detected and measured) could be used on flow cytometers to monitor the major immune cells involved in transplantation.

Dr Hu said, "In the short term, islet transplant recipients do well. However, longer term, we see cases of rejection increase.

"Transplant rejection is a major cause of graft loss and loss of function. It is important that we develop a means of predicting the likelihood of rejection, so that we can intervene.

"We built on existing research and developed a consistent method of using flow cytometry to analyse the immune-cell-count, and subsets of immune cells present in the blood of transplant recipients. This involved the standardisation of a number of factors, such as sample handling and instrument set up.

"We found that this method was easy to use and produced consistent results across a number of samples.

"Importantly, we also found that this method had a very limited impact on the patient - only 1.5mL of blood was required for testing."

Islet transplantation is currently only administered in clinical trials. Dr Hu said the research findings could be used in conjunction with current clinical trials to monitor patients after a transplant.

"Islet transplantation is an important breakthrough for people with type 1 diabetes. If the transplant is tolerated, it can significantly improve the patients' quality of life.

"Unfortunately, we currently have no method of predicting how a patient will respond to a transplant.

"By using this standardised method of flow cytometry to monitor changes in the immune system, this research could help predict whether a patient will reject a transplant, enabling early intervention, and the potential development of other solutions to stop rejection from occurring."
The paper was published in PLOS ONE.

Dr Min Hu is affiliated with The Westmead Institute for Medical Research and The University of Sydney Westmead Clinical Schools.

Westmead Institute for Medical Research

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to